NGNE

+ Watchlist + Portfolio

Neurogene Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.55
52-Week Range: $15.93 – $43.66
Market Cap: $513.29M
P/E (TTM): —
EPS (TTM): -5.04
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.87
PEG Ratio: —
Return on Equity: -45.31%
Return on Assets: -27.98%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.64
Debt/Equity: 0.04
Total Debt: $8.35M
Free Cash Flow: $-48.08M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $296.24M

NGNE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$925.00K	$0.00
Research & Development	$47.51M	$44.39M	$60.92M	$75.01M
Selling, General & Admin	$9.01M	$11.19M	$22.61M	$28.32M
Operating Expenses	$56.52M	$55.58M	$83.53M	$103.33M
Operating Income	-$56.52M	-$55.58M	-$82.61M	-$103.33M
EBITDA	-$51.99M	-$33.01M	-$71.89M	-$87.25M
Pretax Income	-$55.19M	-$36.32M	-$75.14M	-$90.35M
Net Income	-$55.19M	-$36.32M	-$75.14M	-$90.35M
Diluted EPS	-37.80	-73.83	-4.28	-4.24
Diluted Shares	1.46M	4.66M	17.57M	21.33M

NGNE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$82.02M	$148.21M	$136.59M	$103.84M
Receivables	$990.00K	$600.00K	$648.00K	$460.00K
Current Assets	$84.72M	$200.35M	$315.92M	$271.77M
Total Assets	$109.27M	$222.57M	$335.73M	$288.60M
Current Liabilities	$6.65M	$22.97M	$15.16M	$16.41M
Total Debt	$4.69M	$16.25M	$14.24M	$10.96M
Total Liabilities	$255.00M	$36.55M	$25.36M	$23.72M
Retained Earnings	-$150.84M	-$187.15M	-$262.30M	-$352.65M
Shareholders' Equity	-$145.74M	$186.02M	$310.38M	$264.89M
Working Capital	$78.07M	$177.38M	$300.77M	$255.36M

NGNE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$52.82M	-$51.42M	-$70.60M	-$77.17M
Capital Expenditure	-$2.23M	-$321.00K	-$808.00K	-$1.18M
Free Cash Flow	-$55.05M	-$51.74M	-$71.41M	-$78.36M
Depreciation & Amortisation	$3.20M	$3.30M	$3.25M	$3.09M
Stock-Based Compensation	$1.25M	$1.42M	$8.32M	$14.18M
Investing Cash Flow	-$2.23M	$25.64M	-$125.26M	$14.00M
Financing Cash Flow	$66.53M	$92.48M	$184.07M	$30.43M
Net Change in Cash	$11.48M	$66.70M	-$11.79M	-$32.74M

NGNE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.76M	$19.37M	$17.24M	$20.64M	$25.15M	$25.47M
Selling, General & Admin	$8.16M	$6.71M	$6.56M	$6.89M	$8.20M	$11.20M
Operating Expenses	$25.92M	$26.08M	$23.80M	$27.53M	$33.35M	$36.67M
Operating Income	-$25.92M	-$26.08M	-$23.80M	-$27.53M	-$33.35M	-$36.67M
EBITDA	-$21.88M	-$21.25M	-$20.18M	-$23.95M	-$30.08M	-$33.67M
Pretax Income	-$22.65M	-$22.02M	-$20.95M	-$24.73M	-$30.93M	-$34.49M
Net Income	-$22.65M	-$22.02M	-$20.95M	-$24.73M	-$30.93M	-$34.49M
Diluted EPS	-1.08	-1.05	-0.99	—	-1.39	-1.53
Diluted Shares	21.00M	21.06M	21.17M	—	22.31M	22.55M

NGNE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$70.77M	$58.81M	$71.00M	$103.84M	$124.16M	$112.48M
Receivables	$596.00K	$1.31M	$860.00K	$460.00K	$250.00K	$433.00K
Current Assets	$296.40M	$278.99M	$270.52M	$271.77M	$246.75M	$228.91M
Total Assets	$315.30M	$297.32M	$287.83M	$288.60M	$263.14M	$244.36M
Current Liabilities	$14.09M	$15.44M	$14.71M	$16.41M	$18.87M	$21.50M
Total Debt	$13.54M	$12.85M	$11.27M	$10.96M	$9.54M	$8.75M
Total Liabilities	$23.51M	$24.06M	$22.29M	$23.72M	$25.36M	$27.23M
Retained Earnings	-$284.94M	-$306.96M	-$327.91M	-$352.65M	-$383.58M	-$418.07M
Shareholders' Equity	$291.80M	$273.25M	$265.54M	$264.89M	$237.78M	$217.13M
Working Capital	$282.30M	$263.55M	$255.81M	$255.36M	$227.88M	$207.41M

NGNE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$20.77M	-$19.46M	-$19.51M	-$17.43M	-$26.12M	-$23.76M
Capital Expenditure	-$780.00K	-$148.00K	-$127.00K	-$128.00K	-$281.00K	-$354.00K
Free Cash Flow	-$21.55M	-$19.61M	-$19.64M	-$17.56M	-$26.40M	-$24.11M
Depreciation & Amortisation	$762.00K	$767.00K	$776.00K	$787.00K	$854.00K	$820.00K
Stock-Based Compensation	$4.05M	$3.41M	$3.37M	$3.36M	$3.63M	$7.86M
Investing Cash Flow	-$45.05M	$7.45M	$21.99M	$29.61M	$46.24M	$6.10M
Financing Cash Flow	$4.00K	$54.00K	$9.71M	$20.66M	$195.00K	$5.98M
Net Change in Cash	-$65.81M	-$11.96M	$12.19M	$32.84M	$20.32M	-$11.68M

Market Snapshot

About

Neurogene Inc. is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases. The company focuses on adeno-associated virus (AAV)-based gene therapies targeting conditions like Rett syndrome and other genetic neurological disorders. Neurogene uses its proprietary EXACT platform to deliver therapeutic genes directly to the central nervous system.